IDH1 and central nervous system cancer: Ivosidenib (AG-120) has shown positive results in IDH-mutant advanced glioma [10]; other IDH mutation inhibitors, such as AGI-5198 [11], BAY1436032 [12], vorasidenib (AG-881) [13], enasidenib (AG-221) [14], and DS-1001b [15], are still in early clinical development, and their efficacy and toxicity need subsequent studies.